Biotech – the red-hot, high risk investment story

Trump's threat to Europe

Even if he loses, he could destroy the euro

Subscribe now

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

How we can profit from winning the battle against ageing

We’re now living longer than ever – only to suffer from diseases of old age. New therapies promise a new lease of life for the elderly – and big profits for investors, says Matthew Partridge.

Are you ready for the sixth "irruption" in technological innovation?

The industrial revolution paved the way for four further periods of major technological innovation. Now a new wave of change could transform the fortunes of prescient investors, says Nick O’Connor.

Re-engineering the world through your DNA

Gene-editing has the power to completely revolutionise medicine. As Nick O’Connor explains, it could be the most exciting story this century.

How we can avoid the antibiotics apocalypse

As bacteria become resistant to current antibiotics, the race is on to create new compounds. Investors who back winning providers stand to make big gains, says Andrew Lockley.

Three long-term investment ideas for the brave

Professional investor Rebecca O’Keeffe looks at three long-term investment ideas – biotech, Indian equities, and smaller companies – and picks the best ways to invest in each.

Four promising biotech stocks to buy now

The recent correction in biotech stocks was overdone, says professional investor Dr Daniel Koller. Here, he picks four biotech companies to buy now.

Pfizer-Allergan megadeal combines Botox and Viagra

US drug giant Pfizer is to buy Ireland-based Allergan for $168bn, setting a new record for a merger in the pharmaceuticals industry.

Gene editing: a cut-and-paste cure for cancer

Recent advances in the field of gene editing open up a multitude of exciting medical possibilities, says Simon Wilson. But the moral implications should be carefully monitored.

Invest in the future: five game-changing technologies

Over the past 15 years, technology has revolutionised industries across the globe. Matthew Partridge looks at what will shape the next 15.

Chart of the week: biotech spawns a monster

Valuations in the Nasdaq Biotechnology index have soared in recent years. But have we already seen the top?

Showing page 1 of 8